AMSTERDAM, April 21, 2017 /PRNewswire/ -- Royal Philips
(NYSE: PHG, AEX: PHIA) today announced results1 from a
recent study showing significant decreases in both hospital and
payer costs and hospitalization rates for severe chronic
obstructive pulmonary disease (COPD)2 patients. The
study entitled, "Cost Savings from Reduced Hospitalizations with
Use of Home Noninvasive Ventilation for COPD," calculated savings
associated with the use of advanced noninvasive ventilation
(NIV)3, specifically Philips Trilogy 100 with AVAPS-AE
mode, compared to Oxygen therapy alone or the use of less advanced
NIV therapy following patient discharge. The economic model
revealed that both hospitals and payers can benefit from
significant reductions in hospitalizations, readmissions and
healthcare costs while also greatly improving the quality of care
for patients living with COPD.
As one of the most common, underdiagnosed diseases worldwide and
the third leading cause of death in the U.S.4, COPD
continues to be a growing challenge for the healthcare industry.
This disease affects an estimated 384 million individuals
worldwide, while millions more remain undiagnosed5. Not
only is it a major cause of morbidity and mortality, but COPD is a
reason of substantial increases in healthcare costs, mainly due to
the result of inpatient admissions, making it an economic burden
with associated costs estimated to be $50
billion by 20206. Adding to the economic
and personal distress for COPD patients, care is usually
discontinued once discharged from the hospital, often resulting in
re-hospitalization.
In an effort to lessen this burden, the Philips-sponsored study
reviewed how hospitals and payers can more efficiently and
effectively manage this COPD treatment and related comorbidities by
implementing an advanced mode of NIV in the home care setting. This
was reviewed in a multifaceted program that incorporates a
combination of therapies including treatment using advanced NIV
therapy provided by Philips Trilogy100 (AVAPS-AE modality), oxygen
therapy, respiratory therapist-led care, patient education and
medication reconciliation. This at-home program has now proven its
potential to provide both hospitals and payers with tremendous
savings while also offering the patient with treatment at home.
Key findings7 include:
- Hospital Savings: For a hospital covering 250 severe
COPD patients, reduction of readmissions led to cumulative savings
of $402,981 over 30 days and
$449,101 over 90 days with a
multifaceted therapy approach using Philips Trilogy in-home
advanced NIV therapy versus no NIV treatment or less advanced NIV
therapy devices. After examining 1,000 COPD patients being treated
with this same combined treatment method using Trilogy, hospitals
saved $1.6 million in the first 30
days and $1.8 million in 90
days compared to no NIV treatment or less advanced NIV therapy
devices.
- Payer Savings: Payers studying admissions of 100,000
severe COPD patients had cumulative 3-year savings of
$326 million when using home
NIV in comparison to no NIV treatment. Additionally, payers saved
$1.04 billion cumulatively
when using home NIV treatment compared to using a less advanced NIV
therapy device over a three year period.
"The multifaceted and connected home NIV model described in
this study can be easily adopted by other medical
facilities and payers, and is expected to have a
meaningful impact on both clinical outcomes and healthcare
costs," said Dr. Teofilo
Lee-Chiong, pulmonologist and Chief Medical Liaison,
Philips. "As health systems continue to promote value-based
care, it is increasingly important to demonstrate that programs
like these can reduce costs while improving patient experiences
using economic studies."
With COPD being the most common cause for readmissions, this
data supports the role of home care in COPD management. Available
globally, the Philips Trilogy100 device used in this study offers
the unique AVAPS-AE modality designed to tailor treatment and
provide increased support for patients from hospital to home, while
automating the titration process. It is the most widely dispensed
portable ventilator in North
America8. AVAPS-AE advanced mode of ventilation
is also available in Philips BiPAP A40 device available outside
the United States.
This latest study builds on other recent findings, that show how
Philips connected technologies can not only provide seamless care
and improve the patient experience, they can contribute to
significant reductions healthcare costs.
For additional information on Philips' solutions for sleep and
respiratory care, follow @PhilipsResp or visit
www.respironics.com.
For further information, please contact:
Meredith Amoroso
Philips Sleep and Respiratory Care
Mobile: +1 724-584-8991
E-mail: meredith.amoroso@philips.com
Elena Calamo Specchia
Philips Group Press Office
Mobile: +31 6 25004735
E-mail: elena.calamo.specchia@philips.com
About Royal
Philips
Royal Philips
(NYSE: PHG, AEX: PHIA) is a leading health technology company
focused on improving people's health and enabling better outcomes
across the health continuum from healthy living and prevention, to
diagnosis, treatment and home care. Philips leverages advanced
technology and deep clinical and consumer insights to deliver
integrated solutions. Headquartered in the Netherlands, the company is a leader in
diagnostic imaging, image-guided therapy, patient monitoring and
health informatics, as well as in consumer health and home care.
Philips' health technology portfolio generated 2016 sales of
EUR 17.4 billion and employs
approximately 71,000 employees with sales and services in more than
100 countries. News about Philips can be found at
www.philips.com/newscenter.
1 Coughlin, S., Lee-Chiong MD, T. (2017). "Cost
Savings from Reduced Hospitalizations with Use of Home Noninvasive
Ventilation for COPD." Published.
http://www.valueinhealthjournal.com/article/S1098-3015(16)30068-7/abstract
2 Severe COPD was defined as Global Initiative for
Chronic Obstructive Disease(GOLD) stages II to IV.
3 Averaged volume assured pressure support with
autoexpiratory positive airway pressure
4 "How Serious Is COPD." American Lung
Association. Web. 07 Mar. 2017.
5 Adeloye, D. (2015). "Global and regional estimates
of COPD prevalence: Systematic review and meta–analysis."
Published.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693508/
6 Murphy DO, T. (2016). "Is Variation on Following
the GOLD Guidelines Provider Dependent?" Published.
http://journal.publications.chestnet.org/article.aspx?articleid=2568785&resultClick=1
7 Results are based on a single-center initiative and
may vary by institution. See "Cost Savings from Reduced
Hospitalizations" study limitations section.
8 Philips–sponsored market survey study of 120 DMEs
on the brands of ventilators the DMEs set-up for patients in May
2016.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/new-study-with-philips-trilogy-reveals-payers-and-hospitals-can-save-millions-in-readmission-costs-hospitalization-rates-for-copd-patients-300443438.html
SOURCE Royal Philips